Collaborations and Partnerships

To bring the most benefit of our technology platform to physicians and their patients, EyeGate Pharma will look to partner third-party compounds that are in development or are in clinical trials in the field of ophthalmology.

The EyeGate ocular iontophoretic technology is applicable to a broad range of active compounds and is ideal for delivering efficacious dosages in a non-invasive and safe manner. The EyeGate® II Delivery System delivers an increased intraocular drug concentration which is important for treating diseases such as uveitis, AMD (choroidal/retinal neovascularization), glaucoma (neuroprotectants) and diabetic retinopathy.

Core competencies include formulating the ideal medium for delivery of the drug via the EyeGate device, expertise in ocular drug delivery and a comprehensive knowledge of ocular iontophoresis.

If your organization is interested in learning more about EyeGate Pharma and potential product partnering opportunities, please contact us today.